Walk into any pharmacy and CBD is everywhere — gummies, oils, lotions, dog treats. The marketing usually leans on relaxation and sleep. Less well known: CBD has been studied as a possible antipsychotic, and the small body of evidence is genuinely interesting. Less well known still: it is not the same as cannabis, it is not FDA-approved for schizophrenia, and the dose used in trials is very different from what most consumers buy.
CBD shows preliminary evidence of antipsychotic activity in small trials, but it is not a replacement for established schizophrenia treatment, and the over-the-counter products most people buy are not equivalent to research-grade doses.
The two main cannabinoids
Cannabis contains hundreds of compounds. The two best studied are very different from each other:
- THC (tetrahydrocannabinol) is the intoxicating component. It activates CB1 receptors in the brain. High-THC cannabis is associated with increased risk of psychosis, particularly in adolescents and people with genetic vulnerability — see cannabis and psychosis.
- CBD (cannabidiol) is non-intoxicating and acts through different mechanisms — partial agonism at serotonin 5-HT1A, modulation of endocannabinoid signalling, and anti-inflammatory effects. Some animal and small human studies suggest it may have antipsychotic-like activity.
What the trials actually show
The most cited piece of evidence for CBD in schizophrenia is the McGuire et al. trial published in The American Journal of Psychiatry in 2018, with 88 patients comparing CBD 1000 mg/day added to existing antipsychotic treatment versus placebo. The CBD group showed modest improvements in positive symptoms and clinical global impression scores. A handful of smaller trials have produced mixed results — some positive, some null.
What this evidence does not say:
- That CBD is as effective as standard antipsychotics
- That CBD can replace antipsychotic medication
- That over-the-counter CBD products at typical wellness doses (10–50 mg) produce these effects
The dose problem
The trial doses were around 600–1000 mg of pharmaceutical-grade CBD per day. The bottle of CBD gummies you buy at the pharmacy is usually 10–25 mg per gummy. To match a research dose you would need 40–100 gummies a day, which is neither realistic nor advised. There is also enormous variability in actual CBD content of consumer products — independent testing has repeatedly shown that labels often don't match contents.
Drug interactions
CBD is not pharmacologically inert. It inhibits several cytochrome P450 liver enzymes (especially CYP3A4, CYP2C9, CYP2C19), which can raise blood levels of:
- Some antipsychotics, including clozapine and risperidone
- Anticonvulsants such as clobazam and valproate
- Some blood thinners (warfarin)
- Many other commonly prescribed medications
These interactions are particularly relevant in schizophrenia because antipsychotics often have narrow therapeutic windows. Adding high-dose CBD without telling your prescriber can change drug levels in ways that matter.
If you are using CBD — even consumer products at low doses — let your prescriber know. They can check for relevant interactions and consider whether monitoring of medication levels is needed.
What about CBD-rich cannabis?
Some cannabis strains are bred for higher CBD and lower THC content. The cannabis literature suggests these strains may carry less psychosis risk than high-THC products, but they are not neutral — the THC content is reduced, not absent. For someone with schizophrenia, "high-CBD, low-THC" cannabis is still cannabis and still raises relapse risk in most clinical guidance.
Epidiolex: the FDA-approved CBD product
The only FDA-approved cannabidiol product is Epidiolex, indicated for specific seizure disorders (Lennox-Gastaut, Dravet, tuberous sclerosis complex). It is pharmaceutical-grade and dosed precisely. There is no FDA-approved CBD product for schizophrenia, depression, anxiety, or any psychiatric condition.
Anxiety and sleep
Many people with schizophrenia use CBD for anxiety or sleep, often instead of or alongside benzodiazepines. The general-population evidence base for CBD on these symptoms is itself weak, but the practice is common. Reasonable approach: discuss with your prescriber, start low, watch for sedation interacting with antipsychotics (which can already be sedating), and don't substitute CBD for treatment of an underlying sleep disorder.
What this means in practice
If you have schizophrenia and are interested in CBD:
- Tell your prescriber. This is not optional.
- Don't stop or reduce your antipsychotic on the assumption CBD will fill the gap.
- Be aware that consumer products are inconsistent in content and far below research doses.
- If a clinician offers high-dose CBD as adjunct treatment, ask about evidence, monitoring, and whether it is in the context of a research protocol.
- Be sceptical of any vendor or influencer marketing CBD as a cure or replacement for medication.
Where the field is going
Larger trials of CBD as adjunctive treatment in schizophrenia are ongoing. There is also research interest in CBD analogues and other cannabinoid-system targets that don't carry the abuse or psychosis liability of THC. None of this is at the stage of changing first-line treatment.
The honest summary: CBD is interesting and not negligible, but the gap between research-grade doses and consumer wellness products is large, and the gap between "preliminary positive trial" and "established treatment" is larger still.
This article is for educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a qualified mental health professional. If you or someone you know is in crisis, call or text 988 in the US, or your local emergency number.